» Articles » PMID: 39861839

Pregnancy and COVID-19: Comparing ICU Outcomes for Pregnant and Nonpregnant Women

Overview
Journal Viruses
Publisher MDPI
Date 2025 Jan 25
PMID 39861839
Authors
Affiliations
Soon will be listed here.
Abstract

Background: This study compares organ dysfunction, treatment strategies, and unfavorable outcome rates between pregnant and nonpregnant women admitted to the ICU with severe COVID-19, highlighting the increased susceptibility of pregnant women to respiratory infections due to physiological changes.

Methods: A retrospective, age-matched study was conducted at a referral center specializing in critical care for pregnant women. Data from 14 pregnant/postpartum and 11 nonpregnant women were analyzed at ICU admission and on days 3, 5, and 7.

Results: Acute respiratory distress syndrome was diagnosed in 100% of the pregnant/postpartum group and 64% of the nonpregnant group ( = 0.026). Inflammatory parameters were similar between groups, except for lower ferritin levels in the pregnant/postpartum group compared to the nonpregnant (120 vs. 568 µg/L at admission and 90 vs. 616 µg/L on day 3). Creatinine, lactate, and lactate dehydrogenase levels were significantly lower in the pregnant/postpartum group. A reduction in the SOFA score was observed over time in the pregnant/postpartum group (from 7.0 to 4.0 points, = 0.009), while no change was noticed in the nonpregnant group (from 3.0 to 2.5 points, = 0.181). Unfavorable outcome rates were similar, with two patients from each group succumbing to the disease ( = 0.604).

Conclusions: The findings suggest that pregnancy does not increase the risk of unfavorable outcomes among women with severe COVID-19 receiving ICU treatment. However, additional studies with larger sample sizes are needed to validate these observations.

References
1.
Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

2.
Ruscitti P, Berardicurti O, Di Benedetto P, Cipriani P, Iagnocco A, Shoenfeld Y . Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. Front Immunol. 2020; 11:1130. PMC: 7270352. DOI: 10.3389/fimmu.2020.01130. View

3.
Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M . Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect. 2020; 81(4):647-679. PMC: 7313486. DOI: 10.1016/j.jinf.2020.06.053. View

4.
Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

5.
Leal D, Ferreira J, Mansilha A . Thromboembolic risk in pregnant women with SARS-CoV-2 infection - A systematic review. Taiwan J Obstet Gynecol. 2022; 61(6):941-950. PMC: 9500082. DOI: 10.1016/j.tjog.2022.06.012. View